Companies › Waterstone Pharmaceutical (Wuhan)
1 active drug program in 2 registered trials: 2 Phase 3; Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WS016 Potassium binder | – | Phase 3 | Hyperkalemia | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07251309 | WS016 | Phase 3 | Hyperkalemia | Metabolic and endocrine | Nov 2026 |
| NCT07881965 | WS016 | Phase 3 | Hyperkalemia | Metabolic and endocrine | Feb 2029 |
No annotated target.
–
Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group Kowa Company Azafaros
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.